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Introduction
Hirsutism is excessive growth of terminal hair in 
androgen dependant skin areas. Hirsutism may result in 
response to elevated androgen levels and on the contrary 
it may result due to normal androgen levels however with 
increased sensitivity of the hair follicles.1 It is a common 
clinical problem that affects a large percentage of women, 
particularly in the reproductive age.2,3
Lasers were introduced and developed for hair reduction 
to provide a safe, fast and consistent method to reduce 
hair. This method has achieved a worldwide acceptance 
for its effectivness.4 Despite the effectiveness of this hair 
removal method, yet there are some limitations to consider 
when choosing laser and these include pain that could 
be incurred during the sessions, the need for repeating 
the sessions to achieve a satisfactory response and the 
possibility of causing either hyper or hypopigmentation 
and finally the relative higher cost of this method to 
traditional hair removal techniques. Moreover light or 
white colored hair is relatively laser hair removal resistant 
due to its shortage in melanin.5
Capislow extract (an extract from Larrea divaricata 
a shrub that grows in the desert) has been used as a 
topical hair retardant by inhibiting the anagen phase 
of hair growth. This is attributed to it high levels 
of nordihydroguaiaretic acid (NDGA) which has 
antiproliferative, anti-inflammatory, antioxidant, 5 α 
reductase enzyme inhibitor and ornithine decarboxylase 
enzyme inhibitor effects.6-10
Owing to the mentioned actions of capislow, the following 
study setting was designed to examine how much safe and 
effective is combining topical capislow cream and Nd-
YAG laser for treating idiopathic hirsutism. 
Methods
Forty-five female patients (skin type III-IV) with 
idiopathic facial hirsutism, age 18-42 years) were 
included in this study. They were recruited from the laser 
clinic and informed consent was obtained from all study 
participants. They were divided into 2 groups.
Group Ι ( Capislow side): Included a split half face of 
all the included patients treated by combination of long 
pulsed Nd-YAG laser and topical capislow while group 
ΙΙ (Vehicle side) included the same 45 patients with the 
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opposite split side of the face treated with long pulsed Nd- 
YAG laser and placebo.
Only patients and subjects with preexisting facial 
hair of the dark type were recruited and subjected to 
photography. Exclusion criteria included patients with 
recent viral or bacterial active skin diseases, acne vulgaris, 
pregnant or lactating females, anyone with scar history as 
well as patients with hormonal conditions. Patients who 
completed recent laser or radiofrequency sessions in the 
6 months before the study were excluded and those on 
isotretinoin or anticoagulant medications were dismissed 
from joining the study.
Treatment Protocol
Selected patients were subjected to detailed history taking, 
complete clinical examination, laboratory and radiological 
investigations to exclude any cause of hirsutism other 
than the idiopathic type. Patients included in the study 
received sessions using the 1064 nm, long-pulsed Nd:YAG 
laser (Coolglide CV, Cutera, Brisbane, CA). On one split 
side of the face laser was done alone and laser was done 
in combination with topical capislow extract on the 
opposite side, every 4 weeks until 80% of hair reduction 
was achieved for a maximum 7 sessions. Protection of 
the epidermis was achieved using a chill tip in contact 
with the skin during laser firing. Topical 3% capislow 
extract in butylene glycol cream (No Hair Cream®, Mash 
Co. Pharmaceuticals, Egypt) was applied on one side of 
the face while topical placebo (butylene glycol base) was 
applied on the other side daily during the study period 
in a monoblinded manner. Patients were provided with 
anonymous tubes with two different colors (red and blue). 
The patients were asked to put on the red cream on one 
split side of the face and to apply the blue cream from the 
other tube to the other split half of the face. This was done 
throughout the whole study. They were applied once daily 
from the first session then during the study period. No 
laser session was delivered at a scheduled session if the 
hairs were apparent and visible by the naked eye. Follow 
up of the patients continued for up to six months after the 
last laser session. 
Treatment Guidelines 
Preoperative Care
Sun screen, bleaching cream, antivirals and antibiotics 
were used when needed. All hair removal modalities 
except shaving or chemical depilation were stopped 2-4 
weeks before treatment and during the study period. 
Technique
All makeup, skin creams or powders were removed. The 
treatment sessions were performed with the following 
parameters: 
Wavelength (nm): 1064 
Pulse duration (ms): 15-40 
Energy range (J/cm2): 30-45 






Either no decrease or increased visibility of 
terminal hair on the treated site. There could 
be darkening of skin of face
Grade 1
Improved
Clinically obvious decrease in the terminal 





Considerable decrease in visibility of 
terminal hair on the treated site. Only 




Terminal hair not visible at the site of 
treatment. No change in facial skin color
Spot size (mm): 10. 
Each side of the face received identical treatment 
parameters at every session where vaporization of hair 
shaft, perifollicular erythema and edema were set as 
immediate end point for the session provided. No other 
treatment regimen was utilized, and epidermal cooling 
was done by sapphire- hand piece.
Postoperative Care
Following the session, patients were advised to apply a 
mildly potent steroid cream (Mometasone furate) once 
daily for a maximum of 3 days to reduce the erythema 
and/ or perifollicular edema if it was markedly obvious 
in certain sensitive patients, while an antibiotic cream 
(fusidic acid) was indicated twice daily for maximum 5 
days if only epidermal injury had occurred. The patients 
were advised to avoid picking or scratching the area lased 
and to use sunscreen with a sun protection factor of 50. 
Evaluation
Patients were assessed at base line and at every session. The 
remaining assessments were carried out 1, 3 and 6 months 
after the last laser session. Side effects as, dyspigmentation, 
leucotrichia, paradoxical hypertrichosis, scarring and 
inflammations were recorded during each visit. Treatment 
efficacy was evaluated through serial photographs, hair 
counting (using 5 cm2 transparent grid), and rate of hair 
regrowth per month. Independent global evaluations 
were done separately by blinded investigators and patients 
to evaluate hair quality and degree of skin hairiness 
(Table 1).
Punch biopsies (2 mm) were taken from the targeted sites 
bilaterally at base line, at post procedure week, the third 
and seventh sessions, and at the end of the study. Sections 
of hair samples were produced and H&E staining was 
performed. 
Statistical Analysis
Analysis of the study as well as statistical interpretations 
were carried out with the Minitab statistical software 
using chi-square, t test (unpaired and paired) and Man-
Whitney analyses. P value less than 0.05 was regarded and 
Shokeir et al
 Journal of Lasers in Medical Sciences  Volume 9, Number 2, Spring 2018130
accepted as statistically significant. Analysis of variance 
(ANOVA or F test ) was used for comparison of more 
than 2 groups. The analysis was done by a professional 
statistician at our institute.
Results
Sixty-two patients were recruited for the study; 17 of them 
failed to complete the treatments and dropped out while 
45 continued. All included patients were complaining 
from idiopathic hirsutism with a mean age (24 ± 8.6 
years). They were classified into 2 groups according to the 
line of treatment. 
All the included subjects in the study received long pulsed 
Nd YAG laser for 7 sessions along with topical application 
of either capislow on one side of the face group I or placebo 
on the other side group II. The topical treatment was 
stopped at the last session then the patients were followed 
up 1 month, 3 months and 6 months after respectively. 
The number of sessions to reach 80% complete hair 
removal was less and statistically significant P < 0.001 in 
the capislow group (mean ± SD = 4.15 ± 2.1) versus (mean 
± SD = 6.21 ± 3.12) in the placebo group. Starting from 
the fifth session, the hair regression showed significant 
difference towards the capislow side with the most 
significance demonstrated at the seventh session (Table 
2). The rate of hair regrowth was significantly lower at 
the capislow side starting from the third session onwards 
(Table 3).
Global evaluation carried out by investigators was 
significantly positive starting from the third treatment and 
up to one month following the last session (Tables 4 and 5). 
The degree of patient satisfaction paralleled that of the 
investigators and was significant from the third treatment 
onwards, and up to one month following the last session. 
At 3- and 6-month follow up intervals, patient evaluation 
to both modalities returned insignificant satisfaction 
suggesting a temporary and early improvement only 
(Table 6).
Only 2 cases (4.44%) in the (Capislow side) and 9 cases 
(20%) in the (Vehicle side) experienced complications. 
They included erythema, discomfort, burning sensation, 
hyperpigmentation, paradoxical hypertrichosis, 
leukotrichia and inflammation which were insignificant 
among both groups (Table 7).
Moreover, all the patients were screened for liver enzymes 
(SGPT & SGOT) and renal functions (serum creatinine), 





Ist Session 3rd Session 5th Session 7th Session
Nd -YAG and capislow 34.17 ± 19.3 23.4 + 14.7 18.3 ± 3.8 11.6 ± 2.8 21.86 ± 7.24
Nd-YAG and placebo 34.88 ± 20.1 27.9 + 16.5 24.7 ± 8.5 19.36 ± 5.8 26.71 ± 4.25
P value >0.05 >0.055 <0.05* <0.05* <0.05*
*Significant (P < 0.05).





Ist Session 3rd Session 5th Session 7th Session
Nd -YAG and capislow 8.4 ± 3.5 5.41 ± 1.9 4.10 ± 3.4 1.74 ± 0.88 4.28 ± 2.5
Nd-YAG and placebo 8.16 ± 13.7 7.42 ± 3.2 6.11 ± 3.8 4.13 ± 2.1 6.87 ± 3.5
P value >0.05 >0.055 <0.05* <0.05* <0.05*
*Significant (P < 0.05).
Table 4. Comparison Between the 2 Sides Regarding the Global Score of Evaluation During the study Period
The Compared Sides
Points of Comparison 
DifferenceGlobal Score of Evaluation
0 1 2 3
Third session
Nd-YAG and capislow - 21 24 - χ2 = 5.411
P value  = 0.59Nd-YAG and Placebo 9 24 12 -
Fifth session
Nd-YAG and capislow - 18 20 7 χ2 = 20.24
P value = 0.001*Nd-YAG and Placebo 6 28 8  -
Seventh session
Nd-YAG and capislow - 15 17 13 χ2 = 15.72
P value = 0.001*Nd-YAG and Placebo - 24 12 9
*Significant (P < 0.05).
Journal of Lasers in Medical Sciences  Volume 9, Number 2, Spring 2018 131
                                                                                        Topical Capislow for Laser Hair Removal 
for evaluation of topical capislow safety, at the beginning, 
during and at the end of the study and no discovered 
abnormalities were reported (Table 8).
Histological Evaluation
Biopsies taken from both study groups at base line, 
showed a normal hair structure. Histologically, at 
all post treatment sessions, the external root sheath 
appeared normal with mild focal disruption. Some hair 
shafts showed thinning and shriveling due to thermal 
injury whereas some specimens had no shaft due to 
atrophy following treatments. Some specimens showed 
incomplete and uneven disruption of the internal root 
sheath due to the thermal effect of treatment. Increased 
collagen deposition had been noted. All the previous 
changes were equally encountered in biopsies obtained 
from group I (Capislow side) and group II (Vehicle side) 
patients with an exceptional less inflammatory infiltrate 
in the capislow group (Figure 1).
Discussion 
Hirsutism is a medical condition whose hallmark is excess 
growth of dark colored coarse hair in male like pattern. 
The condition affects 5% to 15% of females mostly during 
the child bearing period in androgen dependant sites.11 
Hirsutism represents a severe cosmetic disturbance and 
causes great social and psychological embarrassment 
including anxiety, social avoidance and confusion of 
gender identity.12,13
Idiopathic hirsutism is identified in 10%-15% of women 
who are apparently hirsute, with normal levels of serum 
androgen levels and normal ovulatory and hormonal 
functions.14-16 In the present study, we aimed to evaluate 
whether the combination of physical “(long pulsed Nd-
YAG laser) and pharmacological (topical capislow)” 
method would be superior to long pulsed Nd-YAG 
laser alone in the treatment of idiopathic hirsutism. 
Additionally, we assessed how safe and effective this 
combination is. To our knowledge, this represents the first 
study of its nature and was not carried out before in this 
study setting.
The synergistic significant effect of topical capislow and 
the Nd-YAG laser could be explained by the ability of 
capislow extract to slow terminal hair growth by inhibiting 
the anagen hair cycle phase. The extract contains high 
levels of nordihydroguaiaretic acid (NDGA) which has an 
antiproliferative, anti-inflammatory, 5 α reducase enzyme 
and ornithine decarboxylase enzyme inhibitory effects.17 
Table 5. Comparison Between the 2 Sides Regarding the Global Score of Evaluation During Followup
The Compared Sides
Points of Comparison 
DifferenceGlobal Score of Evaluation
0 1 2 3
One month after Nd-YAG and capislow - 15 17 13 χ2 = 15.72
P value  = 0.001*Nd-YAG and Placebo - 24 12 9
Three months after Nd-YAG and capislow - 19 17 9 χ2 = 5.48
P value = 0.73Nd-YAG and Placebo - 24 15 6
Six months after Nd-YAG and capislow - 21 14 10 χ2 = 6.35
P value = 0.62Nd-YAG and Placebo - 25 12 7
*Significant (P < 0.05).
Table 6. Comparison Between the 2 Sides Regarding the Degree of Patient Satisfaction During the Study Period
  The Compared Sides
Points of Comparison
DifferenceDegree of Patient Satisfaction
No Improvement Fair Average Very Good Excellent
Third session
Nd-YAG and capislow - - 21 24 - χ2 =4.18
P value  = 0.58Nd-YAG and placebo 8 4 32 1 -
Fifth session
Nd-YAG and capislow - - 17 19 9 χ2 =33.87
P value  = 0.001S*Nd-YAG and placebo 4 3 35 3 -
Seventh session Nd-YAG and capislow - - 15 18 12 χ2 =22.60
P value  = 0.002S*Nd-YAG and placebo - 6 28 5 3
*Significant (P ≤ 0.05).
Table 7. Comparison Between the 2 Treated Sides Regarding the Occurrence of Complications During the Study Period
The Compared Sides Complication
Dyspigmentation Whitening of Hair Paradoxical Hypertrichosis Scarring Inflammation Total
Nd -YAG and capislow 1 1 - - - 2
Nd-YAG and placebo 3 1 2 - 3 9
Difference 0.05 >0.05 >0.05 >0.05 >0.05 >0.05
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The inhibitory action of capislow extract on 5 α reductase 
enzyme is mediated by many natural and synthetic 
polyphenolic compounds including NDGA which is 
a highly more effective inhibitor of the type 1 than the 
type 2 isozyme of the 5 α reductase enzyme.6 Moreover 
the anti-inflammatory effect of NDGA is attributed to 
its inhibition of the lipoxygenase and cycloxygenase 
enzymes that are involved in synthesis of leukotriens and 
prostaglandins respectively, which induce the anagen 
phase of hair growth.18 In addition, NDGA is suspected 
to have reversible inhibitory action on the ornithine 
decarboxylase, enzyme involved in the production of the 
hair shaft by induction of the lipogenase inhibitor.19
Histologically, we demonstrated an insignificant 
difference between the 2 studied therapeutic lines except 
for minimal inflammatory infiltrate in the capislow 
treated side. Generally, there was hair shaft destruction 
with follicular damage and more collagen deposition but 
these effects were temporary and thought to be due to the 
thermal effect of laser, as specimens of hair at the end of 
the study showed a more or less normal hair structure. 
This means that in spite of the clinical synergistic effect of 
topical capislow to photoepilation, there were no additive 
effect at the histological level (Figure 2).
The present work agreed to the concept that topical 
capislow is effective, well tolerated and a safe therapy 
for hirsutism. We did not report any skin or systemic 
side effects from topical use of capislow. In spite the 
objection of some authors that NDGA has common 
hepatotoxic and less common nephrotoxic effects, the 
included patients were evaluated for liver enzymes (SGPT 
& SGOT) and renal functions (serum creatinine) before 
and throughout the treatment and it showed no impact. 
This is in accordance with Stickel et al,20 who stated that 
NDGA is toxic only either in systemic large doses of 1.5 
to 3 gm per day for no less than 6 months, or in prolonged 
topical use of concentrations no less than 5%, while the 
concentration used in this study was 3%.
Conclusion 
Topical capislow can represent a safe and effective 
synergistic method for laser with faster results but this 




Normal =up to (7:56 U\L )
SGOT (AST)
Aspartate aminotransferase
Normal = up to (5:40 U\L)
Before Treatment After Treatment P value Before Treatment After Treatment P Value
Treated patients 22.34 ± 3.24 23.12 ± 2.16 > 0.05 21.92 ± 4.29 21.65 ± 7.21 > 0.05
*Significant (P ≤ 0.05).
Figure 1. A cross section in the hair (H&E×250) after 5 sessions (1A) After Nd-YAG laser and placebo showing atrophy of outer and inner root sheaths 
with degeneration and rupture of focal areas of sheath, atrophy of hair shaft, inflammatory cellular infiltrate mainly lymphocytes and the dermis 
shows more collagen deposition. (1B) After Nd-YAG and capislow showing atrophy of the outer and inner root sheaths, atrophy of the hair shaft, 
minimal inflammatory cellular infiltrate and the dermis showing more collagen deposition.
Figure 2. A cross section (H&E×200) after three months of follow up (2A) in the side treated with long pulsed Nd-YAG laser and placebo showing a 
more or less normal structure. (2B)  in the side treated with long pulsed Nd-YAG laser and capislow with a more or less normal structure. 
A B
A B
Journal of Lasers in Medical Sciences  Volume 9, Number 2, Spring 2018 133
                                                                                        Topical Capislow for Laser Hair Removal 





All subjects gave an informed consent to join this study. 
The study has been approved by the research ethics 
committee prior to study beginning.
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